Últimas noticias sobre Sentage Hldgs (NASDAQ:SNTG) Bolsa

Sentage Hldgs

Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.

Freightos Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>), the leading digital freight booking and payment platform for the international freight industry, today reported preliminary key performance indicators for the second quarter of 2025, underscoring the platform's critical role in navigating today's complex trade environment.
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Actuals&#x2A;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Management's Expectations</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Q2 2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Q2 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"># Transactions ('000)</td>
<td colspan="1" rowspan="1">397</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">380 - 385</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Year over Year Growth</td>
<td colspan="1" rowspan="1">26&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">20% - 22%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GBV ($m)</td>
<td colspan="1" rowspan="1">317</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">278 - 285</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Year over Year Growth</td>
<td colspan="1" rowspan="1">56&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">37% - 40%</td>
</tr>
<tr>
<td colspan="4" rowspan="1">&#x2A;Numbers are preliminary and subject to change with the full earnings release</td>
</tr>
</tbody>
</table>
</figure>
Platform Expansion and Network Growth
Freightos continued its robust expansion in Q2 2025, achieving the 22nd consecutive quarter of record transactions and further solidifying its position as an indispensable player in facilitating international trade during times of volatility.
<ul>
<li>Transactions: With 397k Transactions in Q2 2025, representing a 26% year-over-year growth and exceeding management's expectations, Freightos provided essential support in an unpredictable market, underscoring its platform's necessity for real-time adaptability.</li>
<li>Carrier and Buyer Growth: Freightos expanded its network to 75 carriers this quarter, adding prominent airlines such as China Airlines and Air Europa, along with specialized sellers that enhance the platform's service diversity. Meanwhile, unique buyer users grew 6% year-over-year to 20,200, showcasing the platform's broad appeal and customer diversification.</li>
<li>Gross Booking Value (GBV): Carriers and freight forwarders selling on Freightos' platform derived $317 million of revenue from the platform in Q2 2025, representing a 56% year-over-year increase, significantly surpassing management expectations due to the higher transaction volumes and strong contribution from the portal component.</li>
</ul>

News

CRGO

Freightos Hits 22 Straight Quarters of Growth as Global Trade Gets More Chaotic, Sees Record Transactions, $317M Revenue in Q2 2025

Now generally available, 265 customers already reducing hours of work into minutes
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.extremenetworks.com%2F%3Futm_campaign%3D26_PR_Platform-ONE-GA_0000_CORP_AAD_REF_LPG_WW_EN_PRE_home%26utm_medium%3DReferral%26utm_source%3DPR-Platform-ONE-GA%26utm_content%3Dhome&amp;esheet=54290492&amp;newsitemid=20250715875617&amp;lan=en-US&amp;anchor=Extreme+Networks%2C+Inc.&amp;index=1&amp;md5=e08f1f2decdb2231f6e4e874d1feb819">Extreme Networks, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXTR#NASDAQ">EXTR</a>) today announced general availability of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.extremenetworks.com%2Fplatform-one%3Futm_campaign%3D26_PR_Platform-ONE-GA_0000_CORP_AAD_REF_LPG_WW_EN_PRE_PlatformONE%26utm_medium%3DReferral%26utm_source%3DPR-Platform-ONE-GA%26utm_content%3DPlatformONE&amp;esheet=54290492&amp;newsitemid=20250715875617&amp;lan=en-US&amp;anchor=Extreme+Platform+ONE&amp;index=2&amp;md5=e357b6bee7b4e2174e13e2de1018d546">Extreme Platform ONE</a>&#x2122;, making it the first networking vendor to deliver conversational, multimodal, and agentic AI fully integrated into the networking experience. Now, customers can unlock powerful enterprise-wide network visualization, reduce manual work by up to 90%, cut resolution times by up to 98%, and benefit from the industry's simplest licensing. More than 265 customers have already become early adopters of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.extremenetworks.com%2Fnews%2Fnews-details%2F2025%2FExtreme-Networks-Leads-Industry-with-First-All-in-One-Networking-Platform-Powered-by-Conversational-Multimodal-and-Agentic-AI%2Fdefault.aspx%3Futm_campaign%3D26_PR_Platform-ONE-GA_0000_CORP_AAD_REF_LPG_WW_EN_PRE_PlatformONE-LA-PR%26utm_medium%3DReferral%26utm_source%3DPR-Platform-ONE-GA%26utm_content%3DPlatformONE-LA-PR&amp;esheet=54290492&amp;newsitemid=20250715875617&amp;lan=en-US&amp;anchor=Extreme+Platform+ONE&amp;index=3&amp;md5=70fe2f9c19bea93b1576757089256952">Extreme Platform ONE</a>.

EXTR

Extreme Networks Announces General Availability Of Extreme Platform ONE

Management

HSIC

Stanley M. Bergman To Retire As Henry Schein CEO At End Of 2025, Will Continue To Serve As Chairman

APLS

Apellis To Present Five SYFOVRE Abstracts At ASRS 2025, Highlighting Long-Term Efficacy And Safety In Geographic Atrophy

Pure Sunfarms Corp. ("Pure Sunfarms"), a wholly owned subsidiary of Village Farms International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) and one of Canada's leading cannabis producers, has published groundbreaking peer-reviewed research in Scientific Reports (Nature Portfolio), highlighting the natural variability of THC potency within cannabis plants and reinforcing the need for more transparent and accurate labelling across the industry.
The study, led by the Village Farms Canadian Cannabis Research, Development &amp; Lab team, analyzed dried cannabis flower from commercial-scale production. By measuring potency from the top, middle, and bottom of the plant known as strata, researchers observed significant variation in THC levels within individual plants and across different strains.

Village Farms's Pure Sunfarms Publishes Peer-Reviewed Research In Scientific Reports, Highlighting Natural Variability Of THC Potency Within Cannabis Plants

Biotech

Health Care

General

ADAG

Adagene Has Received Written Feedback From The FDA On Its Clinical Development Plan To Evaluate Muzastotug (ADG126) In Combination With Merck's Keytruda For Microsatellite Stable Colorectal Cancer, Patients Enrollment In Phase 2 To Start In 2H 2025

Accelsius, a leader in advanced data center cooling solutions, announced that its proprietary NeuCool&#x2122; IR80 system will be deployed in Q3 2025 at Equinix's Co-Innovation Facility (CIF) in the DC15 International Business Exchange&#x2122; (IBX&#xAE;) data center at the Equinix Ashburn Campus. This dedicated facility provides a platform for Equinix to work with companies that are developing innovative technologies, helping customers see and experience these solutions in action.

Innventure's Accelsius Teams Up with Equinix to Showcase NeuCool IR80 System at Virginia Data Hub

Piper Sandler analyst Derek Podhaizer downgrades Atlas Energy Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) from Overweight to Neutral and maintains the price target from $16 to $16.

Downgrades

Price Target

Analyst Ratings

AESI

Piper Sandler Downgrades Atlas Energy Solutions to Neutral, Maintains Price Target to $16

Ur-Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URG#NYSE">URG</a>)(TSX:<a class="ticker" href="https://www.benzinga.com/stock/URE#TSX">URE</a>) (the "Company" or "Ur-Energy") is pleased to provide an update on Q2 2025 operational and construction progress at its Lost Creek and Shirley Basin in situ uranium projects in Wyoming.
Lost Creek Production and Sales
At our flagship Lost Creek Project, production operations continue to progress with a full operations team on site. Most recently, the construction and startup of header house 2-15 was completed, demonstrating the team's growing efficiency and skill. With training and experience building, our production growth trajectory remains positive.
During the second quarter of 2025, we dried and packaged 112,033 pounds of U3O8, representing a 35% increase over the first quarter 2025;
We shipped 105,316 pounds of powdered uranium concentrate, also known as "yellowcake," to the conversion facility;
At quarter end, our finished inventory at the conversion facility was 315,607 pounds U3O8, and the in-process and drummed inventory at Lost Creek totaled approximately 55,000 pounds U3O8.
In Q2 2025 we sold 165,000 pounds U3O8 at an average price of $63.20 per pound for revenue of $10.4 million.

TSX:URE

Ur-Energy Reports Dried And Packaged 112,033 Pounds Of U3O8 In Q2, Up 35% Over Q1 2025; Co Sells 165K Pounds U3O8 In Q2 At Average Price Of $63.20 Per Pound For Revenue Of $10.4M

LASE

Laser Photonics' CMS Laser Wins New Order From EAP Lasers For Custom CO₂ Drilling System, Signals Strong U.S. Demand

Contracts

ELVA

Electrovaya Receives Additional $4.5M Order Through Its OEM Channel

F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>), the global leader in delivering and securing every app and API, today announced new tools to reduce the immense complexity cross-functional operations (XOps) teams face in managing hybrid, multicloud, and AI-driven application environments. F5 AI Assistant now provides a single natural language interface across F5 BIG-IP, F5 NGINX One, and F5 Distributed Cloud Services offerings to unify the user experience throughout the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.f5.com%2Fproducts%2Ff5-application-delivery-and-security-platform&amp;esheet=54290346&amp;newsitemid=20250715307495&amp;lan=en-US&amp;anchor=F5+Application+Delivery+and+Security+Platform&amp;index=1&amp;md5=d9a5cdfe76272500396bc275242d36bf">F5 Application Delivery and Security Platform</a> (ADSP). As a new feature for the AI Assistant, F5 iRules code generation introduces a scalable, automated solution for teams at all levels of expertise to customize and program solutions for their specific environments.
As organizations increasingly deploy distributed applications and adopt AI solutions, they face increasing pressure to simplify workflows while scaling operations in a fast-evolving digital ecosystem. F5 AI Assistant with iRules code generation helps customers streamline operations by easing configurations, optimizing processes, and unlocking programmability to elevate enterprise application and security management.

FFIV

F5 Launches AI Assistant to Simplify App Management Across Multicloud and AI Systems

MARA

MARA Leads $20M Investment In Two Prime, Expands Bitcoin Allocation To 2,000 BTC To Boost Institutional Yield Strategy

Aquestive Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that Health Canada has granted the Company a meeting to discuss Aquestive's planned New Drug Submission (NDS) for Anaphylm&#x2122; (epinephrine) Sublingual Film in Canada. In addition, the Company has submitted an initial briefing book to the European Medicines Agency (EMA). The Company plans to submit a Marketing Authorization Application (MAA) to the EMA as soon as possible.
"These regulatory activities mark the pivotal first steps in Aquestive's comprehensive ex-U.S. regulatory strategy," said Dan Barber, President and Chief Executive Officer of Aquestive. "With our U.S. FDA New Drug Application recently accepted and a PDUFA target action date of January 31, 2026 established, we're now positioned to pursue parallel regulatory pathways with the potential to bring needle-free, device-free Anaphylm to patients underserved by current treatment options. Our proven ability to successfully bring innovative therapies to market globally, combined with our oral epinephrine approach, positions us to fundamentally change how patients and caregivers manage severe allergic reactions, including anaphylaxis."
Aquestive brings significant regulatory and commercialization experience to this expansion effort, with six FDA-approved drugs in its portfolio and products currently available across six continents. This established global footprint and regulatory track record positions the Company to efficiently navigate international approval processes.
Unlike traditional epinephrine auto-injectors that require needles, Anaphylm&#x2122; is administered orally, addressing critical barriers to treatment, including needle phobia, device malfunction concerns, and portability challenges that affect patient compliance and emergency response.
The Company's ex-U.S. regulatory strategy prioritizes markets with significant unmet medical needs and regulatory frameworks conducive to innovative therapies. EMA and Canada represent ideal initial international markets given their collaborative regulatory environment and substantial population of patients requiring reliable anaphylaxis treatment options.
Aquestive will continue to provide updates on its global regulatory approval progress as it works to establish Anaphylm as the new standard of care for the treatment of severe allergic reactions and anaphylaxis worldwide.

AQST

Aquestive Seeks Approval for Needle-Free Allergy Film in Canada and Europe, Eyes Global Expansion

TECH

Bio-Techne Partners To Distribute Spear Bio's Ultrasensitive Immunoassays, Enabling The Detection Of Low-abundance Biomarkers In Neurology, This Partnership Follows Bio-Techne's Participation In Spear Bio's $45M Series A Funding Round In 2024

JP Morgan analyst Adrian Huerta initiates coverage on Amrize (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRZ#NYSE">AMRZ</a>) with a Overweight rating and announces Price Target of $57.

Initiation

AMRZ

JP Morgan Initiates Coverage On Amrize with Overweight Rating, Announces Price Target of $57

GXO Signs Multi-Year Logistics Deal With Sky Italia To Manage Supply Chain, Storage, And Value-Added Services At Colleferro Site

Acuren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIC#NYSE">TIC</a>) ("Acuren") today announced the expiration of the 60-day "go-shop" period ("Go-Shop Period") in connection with the previously announced Agreement and Plan of Merger with NV5 Global, Inc. (("NV5", NASDAQ:<a href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>), dated as of May 14, 2025 (the "Merger Agreement").
During the Go-Shop Period, NV5 was permitted to solicit and enter into negotiations with third parties that made a proposal or offer to acquire NV5. The Go-Shop Period expired at 11:59 p.m. ET on July 14, 2025. NV5 did not receive an NV5 Superior Proposal (as such term is defined in the Merger Agreement) during the Go-Shop Period.
The transactions contemplated by the Merger Agreement (the "Transactions") are expected to close in August of 2025, subject to customary closing conditions, including approval of each of Acuren and NV5's stockholders and receipt of regulatory approvals.

NVEE

Acuren Announces Expiration Of 60-Day "Go-Shop" Period In Connection With Agreement And Plan Of Merger With NV5 Global

SXTP

60 Degrees Pharmaceutical Determines Maximum Size Of Commercial Market For ARAKODA In Human Babesiosis To Be 380,000 Patients And $245M In Sales Annually

RFIL

RF Industries Secures $2.3M Follow-On Orders From Leading Aerospace Firm For Mission-Critical Custom Cabling Solutions

Earnings

Press Releases

Sentage Holdings Inc. Announces Financial Results for the First Six Months of Fiscal Year 2024

Comments

Sentage Hldgs

Noticias

Últimas noticias sobre Sentage Hldgs (NASDAQ:SNTG) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL